Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Iomeprol (B16880) is a new non-ionic tri-iodinated radiographic contrast medium. It was the aim of this double blind randomized phase III clinical trial to compare the local and systemic tolerance of iomeprol-300 (300 mg I ml-1) with the commercially available iopromide-300 (300 mg I ml-1) in a group of 198 patients needing intravenous urography. The contrast medium was injected rapidly into an antecubital vein within 2-3 min in most cases, using a standard dosage of 1 ml kg-1 body weight. The proportion of patients with an allergic diathesis was 25% in the iomeprol group and 17.3% in the iopromide group. There were no life-threatening adverse reactions. Eight patients (8%) receiving iomeprol and 6 (6.1%) receiving iopromide had a sensation of heat related to the injection of contrast medium. Only one patient (1%) in the iomeprol group and two patients (2%) in the iopromide group noted pain on injection. Although the incidence of all other side-effects was relatively high (7% after iomeprol and 11.2% after iopromide) these reactions were generally harmless. The most common symptom was nausea and/or vomiting, which occurred with the same incidence (5%) in both groups. Only one patient in each group developed urticaria or erythema. Vital parameters remained essentially unchanged in all patients. The results suggest that iomeprol is a safe contrast medium, with a tendency to produce fewer side effects than iopromide, which is known to be particularly well tolerated.
 ...
PMID:Iomeprol versus iopromide for intravenous urography. 800 Aug 39

Iomeprol, a new nonionic contrast medium, was administered at concentrations of 300 mgI/ml, 350 mgI/ml, and 400 mgI/ml to 1939 Japanese patients. The radiographic efficacy, the incidence of heat sensation and the incidence of pain were evaluated. The radiographic efficacy was rated as excellent in 80.6% and good in 17.5% of 1017 cases of conventional arteriography, excellent in 75.6% and good in 22.2% of 267 cases of IADSA or IVDSA, excellent in 78.3% and good in 19.6% of 384 cases of intravenous urography and excellent in 68.6% and good in 28.8% of 271 cases of CT enhancement. There was no statistical difference in radiographic efficacy between the sites of arteriography. Heat sensation was mild or moderate in 43.4% and severe in 0.2% of cases requiring intra-arterial injection, and mild or moderate in 50.7% of cases requiring intravenous injection. There were no cases of severe heat sensation following intravenous injection. The incidence of pain was low (mild 4.2%, moderate 0.7% and severe 0.1%) with intra-arterial injections. It is concluded that iomeprol is an excellent radiographic contrast medium for intravenous urography, CT enhancement and various forms of angiography.
 ...
PMID:Evaluation of the radiographic efficacy of iomeprol. 802 May 12

In a randomized double-blind study in 50 patients (38 men, 12 women of medium age 52.2 +/- 8 years) the new non-ionic low-osmolal x-ray contrast agent Iomeprol 400 is compared with the high-osmolal contrast medium natrium-meglumine-diatrizoate (Urografin 76). Electrocardiographic, hemodynamic as well as general effects and side-effects such as bradycardias, tachyarrhythmias, allergic reactions, attacks of hyperhidrosis, nausea, vertigo, thoracal pain, cephalgies after selective coronary angiography and levocardiography were registered. Between the two groups of patients there were no major differences concerning age, sex, weight, and coronary status. After coronary angiography in the two groups the following parameters were statistically significant: Iomeprol 400 led to a smaller reaction of heart rate (P = 0.001 during left coronary injection or P = 0.003 during right coronary injection), to a lower rise of the QT-time (P = 0.0005 for right coronary injection or P = 0.0001 for left coronary injection) as well as to a mild change of the T-vector (P = 0.0002 in right coronary injection or P = 0.0001 in left coronary injection). After levocardiography using natrium-meglumine-diatrizoate versus Iomeprol 400 a significantly stronger decrease in systolic (P = 0.0001) and diastolic (P = 0.0001) aortic pressure was registered. The increase of heart rate was less frequent with Iomeprol 400 than using the ionic contrast medium, which was compared to it (P = 0.048). In the general effects with Iomeprol 400 a statistically significantly less frequent appearance of bradycardias was registered (P = 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Electrocardiographic and hemodynamic adverse effects of contrast media in coronary angiography]. 816 45